Latest Janssen Research & Development LLC Stories
RARITAN, N.J. and SAN ANTONIO, Dec.
Follow-up data from the Phase 2 PCYC-1104 trial presented at the American Society of Hematology Annual Meeting show sustained efficacy and safety over time SAN FRANCISCO and RARITAN, N.J.,
IMBRUVICA data presented at the American Society of Hematology Annual Meeting show 79 percent of CLL patients with del 17p were progression-free at 12 months SAN FRANCISCO and RARITAN, N.J.,
Additionally, Trabectedin Expanded Access Program Now Allows Entry of Eligible Patients with Previously Treated Advanced Soft Tissue Sarcoma, Including those with Liposarcoma and Leiomyosarcoma
First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults TITUSVILLE, N.J., Nov.
- Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4454, 4469, 4680 RARITAN, N.J., Nov.
RARITAN, N.J., Nov.
LONDON, SUNNYVALE, Calif. and RARITAN, N.J., Nov.
The Program is Jointly Funded by LLS and Janssen Research & Development, LLC WHITE PLAINS, N.Y., Oct.
Latest submission seeks approval for additional blood cancer indication RARITAN, N.J., Oct.
- The act of sweetening by admixture of some saccharine substance.